PHAT - Rasio utang marang kapitalisasi buku Phathom Pharma

Phathom Pharmaceuticals (PHAT) operates in a stable environment with minimal external risks and diversified logistics. The business relies on a therapeutic system centered around Voquezna, which creates sustainable customer loyalty. This price chart demonstrates the asset's dynamics, with a metric of 0.00. Revenue is generated through the sale of prescription drugs for individuals with gastrointestinal pathologies via pharmacies, supported by US insurance systems.

This indicator measures the debt load relative to equity, allowing for an assessment of financial stability and the degree of the business's dependence on borrowed funds. By analyzing the current debt-to-equity ratio of Phathom Pharmaceuticals (PHAT), an investor can weigh leverage risk against the profit growth potential from the sale of Voquezna, which determines the overall safety of the asset within a portfolio.